What is the milligram dose delivered by 0.25 mL of a 200 mg/mL intramuscular testosterone preparation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Dose Calculation for Intramuscular Testosterone

0.25 mL of a 200 mg/mL testosterone preparation delivers 50 mg of testosterone.

Simple Calculation

The calculation is straightforward:

  • Concentration: 200 mg/mL 1
  • Volume: 0.25 mL
  • Dose = 200 mg/mL × 0.25 mL = 50 mg

Clinical Context

The FDA-approved testosterone cypionate formulation is standardized at 200 mg/mL 1. This concentration is consistent across intramuscular testosterone preparations, making dose calculations uniform.

Common Dosing Regimens

Based on the available evidence, typical intramuscular testosterone dosing includes:

  • 100 mg weekly - Associated with lower risk of erythrocytosis (1% incidence of hematocrit >54%) 2
  • 200 mg every 2 weeks - Standard replacement regimen that maintains eugonadal testosterone levels through day 11 3, 4
  • 200 mg weekly - Higher dose used in contraceptive trials, associated with 8% incidence of elevated hematocrit 2

Clinical Significance of 50 mg Dose

A 50 mg dose (0.25 mL) represents:

  • Half of the typical weekly dose when using a 100 mg weekly regimen
  • One-quarter of the standard biweekly dose of 200 mg

This lower dose may be appropriate for:

  • Dose titration during therapy initiation
  • Patients requiring lower maintenance doses
  • Subcutaneous administration protocols (though 50 mg weekly subcutaneous testosterone enanthate has been studied and achieved mean steady-state levels of 422 ng/dL) 5

Important Monitoring Considerations

Intramuscular testosterone carries specific risks that require monitoring, particularly erythrocytosis, which occurs more frequently with injections than transdermal preparations (43.8% vs 15.4% had at least one elevated hematocrit with IM vs transdermal) 6. The risk increases with higher doses and supraphysiologic testosterone levels 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.